Benlysta continues to penetrate lupus market one year post-launch; report
More than two-thirds of surveyed rheumatologists have initiated trial of GlaxoSmithKline (LSE: GSK) and Human Genome Science’s (Nasdaq: HGSI) lupus drug Benlysta (belimumab), up from 51% in Wave 3 (six months post-launch) and significantly higher than all previous waves in the LaunchTrends: Benlysta report series, from Decision Resources’ BioTrends unit.
One of the most notable shifts in prescribing since one month post-launch is a significant increase in current Benlysta shares for the moderate and severe patient groups, the report notes. BioTrends surveyed 101 rheumatologists and conducted qualitative interviews with a subset of 15 of the respondents in April 2012. This is the final report of this series.
Cost still a concern
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze